Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples